Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 46.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 19,740 shares of the biopharmaceutical company’s stock after purchasing an additional 6,259 shares during the period. Jefferies Financial Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,309,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone formation and progressive loss of movement. Approval gives Regeneron a new commercial product and strengthens its rare-disease portfolio. However, the small patient population may limit its immediate contribution to earnings. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: A Sound Shore Management investor letter highlighted Regeneron’s need to adjust its strategy following mixed results in melanoma drug trials. The commentary reflects ongoing investor debate about the company’s pipeline and long-term growth, while other market coverage indicates Wall Street remains reasonably constructive on the broader outlook. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Multiple law firms announced or promoted a securities class action concerning allegations that Regeneron misled investors about the prospects of the Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial failure reportedly caused a major selloff and an approximately $11 billion decline in market capitalization. The allegations have not been proven, but the litigation adds reputational, legal, and disclosure risk; the lead-plaintiff deadline is September 14, 2026. Regeneron Investors Have Opportunity to Lead Class Action Lawsuit

Regeneron Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ:REGN opened at $807.71 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $713.83 and a two-hundred day moving average of $717.85. The stock has a market cap of $83.16 billion, a P/E ratio of 19.96, a PEG ratio of 1.39 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.81 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on REGN. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Leerink Partners raised their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research report on Monday, August 17th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Barclays dropped their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Fifteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $800.36.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the sale, the director directly owned 603 shares in the company, valued at approximately $482,400. The trade was a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 in the last ninety days. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.